Biomedicine & PharmacotherapyCell BiologyPeer-reviewed journal article
Diosmetin alleviates liver inflammation by improving liver sinusoidal endothelial cell dysfunction.
D. Zurawek, N. Pydyn, P. Major, K. Szade, K. Trzos, E. Kus, E. Pospiech, P. Malczak, D. Radkowiak, A. Budzynski, S. Chlopicki, J. Jura, J. Kotlinowski
Abstract
Background & AimsTumor necrosis factor-alpha (TNF) induces pro-inflammatory activation in liver sinusoidal endothelial cells (LSEC) and liver inflammation. However, knowledge about whether modulating LSEC activation can alleviate liver inflammation is scarce. This study aimed to establish and validate an animal model mimicking LSEC dysfunction observed in patients with elevated plasma levels of TNF, and explore whether vasoactive flavonoid diosmetin could serve as a therapeutic agent for liver inflammation. Approach & ResultsGenetic deletion of Mcpip1 in myeloid leukocytes (Mcpip1fl/flLysMCre) resulted in the development of systemic and liver inflammation in mice. Symptoms were compared with those in liver samples from obese humans with elevated TNF. Mice were treated with diosmetin, and its effectiveness in alleviating liver inflammation was evaluated. Elevated TNF correlated with reduced Mcpip1 expression in peripheral blood mononuclear cells and LSEC dysfunction in obese patients. Mcpip1 knockout in myeloid cells in mice replicated molecular signs observed in human samples. Diosmetin efficiently reduced LSEC activation and liver inflammation in Mcpip1fl/flLysMCre mice. Diosmetins effects may stem from inhibiting NF-{kappa}B-p50 subunit production in TNF-activated endothelial cells. ConclusionsDiosmetin treatment efficiently restricted liver inflammation, despite ongoing systemic inflammation, by diminishing LSEC dysfunction. Mcpip1fl/flLysMCre mice mimic symptoms of liver inflammation observed in humans and can be useful in studies on new anti-inflammatory therapies for the liver. We show that diosmetin, a vasoactive flavonoid that is successfully used in the clinic to treat chronic venous insufficiency, has also strong anti-inflammatory properties in the liver. This suggests that diosmetin treatment may be tested in humans as a supportive therapy for liver inflammation. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=186 HEIGHT=200 SRC="FIGDIR/small/563468v1_ufig1.gif" ALT="Figure 1"> View larger version (48K): org.highwire.dtl.DTLVardef@1c1c841org.highwire.dtl.DTLVardef@1425cb9org.highwire.dtl.DTLVardef@1d583aaorg.highwire.dtl.DTLVardef@b71f40_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: mouse
- research focus: host-pathogen & immune response
- research focus: drug response / drug discovery
- research focus: cell type annotation
- research focus: differential expression
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Liver sinusoidal endothelial cells orchestrate NK cell recruitment and activation in acute inflammatory liver injury
S. Papaioannou, J.-X. See, … A. Stojanovic·bioRxiv·Jul 15, 2022
- Differential effects of fenofibrate and fenofibric acid on the regulation of liver endothelial permeability
Marcin Luty, Dibakar Borah, … Bartłomiej Zapotoczny·bioRxiv·Apr 20, 2026
- Myricetin Attenuates LPS-induced Inflammation in RAW 264.7 Macrophages and Mouse Models
- Tirzepatide reduces diet-induced senescence and NETosis-mediated liver fibrosis in mice
Feng Chen, QiQi Nam, … Siu Ling Wong·bioRxiv·May 27, 2025
- FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis
C. Liu, M. Schönke, … P. C. Rensen·bioRxiv·Sep 20, 2022
- Increasing plasma bile salt levels with Bulevirtide alleviates DSS-induced colitis and LPS-induced inflammation
Thuc-Anh Nguyen, Reinout L.P. Roscam Abbing, … Stan F.J. van de Graaf·bioRxiv·Apr 23, 2026